MedPath
Found 2 clinical trials|View Analysis
Sort by:

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)

Phase 3
Recruiting
Conditions
Advanced Melanoma
Interventions
Biological: Vusolimogene Oderparepvec
Biological: Nivolumab + Relatlimab
Biological: Nivolumab
Biological: Pembrolizumab
Drug: Single-agent chemotherapy
First Posted Date
2024-02-16
Last Posted Date
2024-12-24
Lead Sponsor
Replimune Inc.
Target Recruit Count
400
Registration Number
NCT06264180
Locations
🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

The Angeles Clinic and Research Institute, Los Angeles, California, United States

🇺🇸

USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 17 locations

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Early Phase 1
Recruiting
Conditions
Melanoma
Interventions
Biological: Vusolimogene oderparepvec (RP1)
First Posted Date
2024-01-22
Last Posted Date
2024-03-04
Lead Sponsor
Yana Najjar
Target Recruit Count
25
Registration Number
NCT06216938
Locations
🇺🇸

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath